论文部分内容阅读
我院于１９９２年开始应用多聚酶链反应（ＰＣＲ）技术，对同种异体肾脏移植的供受者ＨＬＡ－Ⅱ类抗原进行基因分型。通过４０例患者基因分型结果表明：肾移植患者供受者有１～２个ＨＬＡＤＱＡ等位基因相符者，移植肾１年存活率１００％；完全不相符者，１年存活率３３％，两者有非常显著性差异（Ｐ＜０．００５）。采用此方法对器官移植供受者进行基因分型，可大大提高供受者间组织相容性相符程度，减少或减轻排斥反应的发生，以期提高移植物的存活质量，获得更好的临床效果。
Our hospital began in 1992 by polymerase chain reaction (PCR) technology, allogeneic renal transplant recipients of HLA-Ⅱ antigen genotyping. According to the results of genotyping in 40 patients, 1 to 2 HLADQA alleles were matched for donor recipients and 1-year survival rate for transplant recipients was 100%. Completely unqualified patients showed a 1-year survival rate of 33% There was a very significant difference (P <0.005). Using this method to genotype the donor for organ transplantation can greatly improve the consistency of donor-recipient histocompatibility and reduce or reduce the incidence of rejection in order to improve the graft survival and obtain better clinical results .